Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Nicaise Claude reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Claude Nicaise received a grant of 16,875 shares of common stock in the form of restricted stock units (RSUs). The RSUs were granted at no cash cost per share and increase his directly held position to 48,407 shares of common stock.
Each RSU represents the right to receive one share of Sarepta common stock. The RSUs will vest on the earlier of one year from the grant date or the next annual meeting of stockholders that occurs at least 50 weeks after the prior year’s annual meeting, aligning vesting with the company’s annual meeting cycle.
Chambers Michael Andrew reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics director Michael Andrew Chambers reported an equity award of 16,875 shares of common stock in the form of restricted stock units. The RSUs were granted at no cash cost per share and will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided it occurs at least 50 weeks after the prior annual meeting. Following this grant, Chambers holds 27,535 shares directly, in addition to 476,492 shares held indirectly through a revocable trust.
Barry Richard reported acquisition or exercise transactions in this Form 4 filing.
Sarepta Therapeutics, Inc. reported that director Barry Richard received a grant of 16,875 shares of Common Stock as restricted stock units (RSUs) at a price of $0.00 per share. These RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that is at least 50 weeks after the prior year's annual meeting.
Following this grant, Richard directly holds 2,983,542 shares of Sarepta common stock. He also has indirect ownership of 10,000 shares through an LLC and 240,000 shares through a trust, as reported in the filing.
Sarepta Therapeutics, Inc. reported results from its annual stockholder meeting. Stockholders approved the new 2026 Equity Incentive Plan, which allows issuance of up to 6,286,841 shares of common stock under future awards, replacing the prior 2018 equity plan.
They also approved a new 2026 Employee Stock Purchase Plan, making 1,500,000 shares available for employee purchases and replacing the amended 2013 ESPP. All Class I director nominees were elected for two-year terms, executive compensation for 2025 received advisory approval, and KPMG LLP was ratified as independent auditor for the year ending December 31, 2026.
Sarepta Therapeutics, Inc. submitted a Form 13F holdings report signed by Ryan Wong on 05-13-2026. The report lists 1 Form 13F information table entry with a total reported value of $0 and shows 0 other included managers. The filing attests that the signatory is authorized and that the information is true and complete.
Sarepta Therapeutics reported a sharp swing to profitability in the first quarter of 2026 while advancing its Duchenne and RNA pipelines. Total revenues were $730.8 million, down slightly from $744.9 million a year ago, as lower ELEVIDYS product volume from an ambulatory‑only label was offset by higher collaboration and contract manufacturing revenues, including $365.0 million tied to Roche’s declined option and a $40.0 million ELEVIDYS launch milestone in Japan.
GAAP operating income reached $358.4 million versus a loss of $300.4 million, and GAAP net income was $331.0 million compared with a $447.5 million loss, reflecting reduced R&D and SG&A after a 2025 pipeline reprioritization and the absence of prior Arrowhead upfront charges. Non‑GAAP operating income was $397.7 million and non‑GAAP net income was $385.4 million.
The company ended March 31, 2026 with $748.3 million in cash, cash equivalents, restricted cash and investments, down from $953.8 million at year‑end, and reaffirmed 2026 guidance for total net product revenues of $1.2–$1.4 billion and combined non‑GAAP R&D and SG&A expenses of $800.0–$900.0 million. Sarepta highlighted early Phase 1/2 siRNA data in FSHD1 and DM1, progress in ENDEAVOR Cohort 8 using sirolimus pretreatment for ELEVIDYS in non‑ambulatory Duchenne patients, and sNDAs seeking traditional approvals for AMONDYS 45 and VYONDYS 53.
Sarepta Therapeutics Inc is reported as having 5,369,116 shares beneficially owned by Vanguard Capital Management, representing 5.11% of the common stock. The filing states Vanguard has sole voting power for 790,881 shares and sole dispositive power for 5,369,116 shares. The disclosure attributes ownership across Vanguard affiliates as described in the filing.
Sarepta Therapeutics: Vanguard Portfolio Management reports ownership of 6,751,168 shares of Common Stock, representing 6.43% of the class. The filing states Vanguard has sole dispositive power over 6,751,168 shares and sole voting power over 110,476 shares. The statement is signed by Ashley Grim on 04/29/2026.